Jefferies Group Research Analysts Lift Earnings Estimates for Sanofi SA (SNY)
Sanofi SA (NYSE:SNY) – Research analysts at Jefferies Group increased their FY2017 earnings per share (EPS) estimates for shares of Sanofi in a research report issued to clients and investors on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings of $3.45 per share for the year, up from their prior estimate of $3.18. Jefferies Group also issued estimates for Sanofi’s FY2018 earnings at $3.42 EPS and FY2022 earnings at $4.75 EPS.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $1.00 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.00. Sanofi had a return on equity of 25.19% and a net margin of 25.44%.
Sanofi (NYSE:SNY) opened at $44.91 on Wednesday. The firm has a market capitalization of $112,913.13, a price-to-earnings ratio of 11.46, a PEG ratio of 2.58 and a beta of 0.87. Sanofi has a 52-week low of $39.42 and a 52-week high of $50.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16.
Institutional investors have recently bought and sold shares of the stock. Bank of Nova Scotia Trust Co. purchased a new position in Sanofi during the third quarter worth about $125,000. YorkBridge Wealth Partners LLC grew its position in Sanofi by 33.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after buying an additional 776 shares in the last quarter. Toronto Dominion Bank grew its position in Sanofi by 4.6% during the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after buying an additional 180 shares in the last quarter. Mraz Amerine & Associates Inc. purchased a new position in Sanofi during the third quarter worth about $204,000. Finally, River Road Asset Management LLC purchased a new position in Sanofi during the third quarter worth about $208,000. Institutional investors and hedge funds own 9.08% of the company’s stock.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.